| Financial and Operational Strength
As of the third quarter 2025, VNRX reported a cash position of approx. $12.3Mn.
The company has been disciplined in its capital allocation, focusing on high-value commercial partnerships and streamlining its manufacturing processes.
The management team, led by CEO Cameron Reynolds, brings decades of experience in the biotechnology sector, specifically in bringing novel diagnostic tools to global markets.
Grab Sources And More Here: VNRX Website. VNRX Presentation. -----
And as I mentioned earlier, (NYSE American: VNRX) has several potential catalysts of focus. Take a look:
#1. VNRX Potential Catalyst - A Significant Analyst Target ($2.50) May Signal Triple-Digit Potential Upside.
Recently, Zacks Small-Cap Research analyst, Steven Ralston, provided coverage on (NYSE American: VNRX) with a price target of $2.50.
From Friday's closing valuation, this target suggests a potential upside of 750+%.
Here's some report highlights:
Outlook:
Management’s primary operational goal for 2025 is (was) to secure multiple licensing agreements for human diagnostic applications. In September Volition entered into two such licensing agreements.
The company’s 1st commercial order for Nu.Q Cancer assays was received in November.
The key financial goal for 2025 is (was) to achieve cash neutrality on a full-year basis. In 3Q 2025, cash burn was reduced to 1.2Mn per month.
Papers, posters, conference presentations, webinars etc. continue on a brisk pace. -----
#2. VNRX Potential Catalyst - A Major Breakthrough Announced In Nu.Q® Vet Cancer Test Clinical Data.
VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats
Paves the Way for World's First Feline Liquid Biopsy Test for Cancer Detection
HENDERSON, Nev., Jan. 8, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces results from a clinical study demonstrating the high accuracy of its Nu.Q® Vet Feline assay in detecting lymphoma in cats, the most common cancer in the species. At 100% specificity, i.e. no false positives, the assay detected over 80% of feline lymphomas. This breakthrough marks the development of what we expect to be the world's first simple, affordable blood-based liquid biopsy test for feline cancer, a significant unmet need in veterinary medicine.
Frédéric Wuilque, VP-Global Products, Volition commented:
"Historically, cancer in cats has been notoriously difficult to diagnose early, often requiring invasive biopsies or expensive imaging after symptoms have already progressed. Veterinarians have been asking for a feline solution for years.
Our mission is to make cancer screening a routine part of every pet's annual wellness check and following the successful international rollout of our canine cancer test, we have now demonstrated that our technology is also effective for cats.
We look forward to completing product development and making the Nu.Q® Vet Feline Test available through our existing distribution networks including reference laboratories and point-of-care platforms."
...
Read the full article here. -----
#3. VNRX Potential Catalyst - The Company Just Solved A "Needle In A Haystack" Problem With 180-Fold (18,000%) Enrichment.
Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment
HENDERSON, Nev., Dec. 11, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces preprint availability of a new manuscript entitled "Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: Measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy." This paper showcases both a new method, Capture-Seq™, and new biomarkers for the detection of cancer, holding the promise of accurate, low-cost tests for a wide range of cancers.
Physical enrichment of ultrashort DNA fragments bound to a transcription factor is a key breakthrough allowing for the quantification in blood of combinations of potentially hundreds of binding sites associated with cancer that represent a new class of ultrashort DNA biomarkers not available to previous DNA analysis methods. Volition has achieved 180-fold enrichment (18,000%) through our unique focus on chromosome fragments – the form in which DNA actually exists in the blood. In contrast, current methods focus on the DNA itself after it has been chemically extracted from the blood, when its context within a chromosome has been lost.
Dr Jake Micallef, Chief Scientific Officer, Volition commented:
"This is, I believe, a world-first breakthrough – it is the first time that transcription factor-bound DNA has been physically separated from the massive amounts of background DNA in the blood, and could, in my opinion, represent the biggest scientific breakthrough in cancer testing in recent years.
There is excitement in the world of liquid biopsy cancer DNA testing around the recent discoveries of ultrashort DNA fragments in the blood (including transcription factor-bound DNA), which hold great promise not only for accurate low-cost early cancer detection and cancer management, but also potentially for identifying the type of cancer present.
Previous DNA liquid biopsy tests involve extraction of all DNA in the blood. A challenge faced by current technologies is that the overwhelming majority of DNA extracted from the blood is not cancer related but in fact "background" DNA. This background DNA interferes in DNA based liquid biopsy tests, especially tests for early-stage cancer. However, by isolating ultrashort DNA fragments bound to transcription factors using an antibody, Volition's technology removes 99% of background DNA before DNA extraction. Only ultrashort transcription factor-bound DNA is extracted and sequenced and the background DNA is washed away, solving the classic needle in a haystack problem. Moreover, this ultrashort transcription factor-bound DNA holds a great deal of additional information not available in the remaining 99% of DNA."
...
Read the full article here. -----
#4. VNRX Potential Catalyst - Volition Presents Two Abstracts At The NACLC (Now On the Path To The First Use Of Nu.Q® In Clinical Practice.
Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer
HENDERSON, Nev.,, December 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of two abstracts at the North America Conference on Lung Cancer (NACLC) in Chicago recently. The posters highlighted the use of its Nu.Q® Cancer assays in the management of lung cancer patients.
...
Dr Andrew Retter, Chief Medical Officer of Volition, said:
"Nu.Q® Cancer represents a significant advancement in lung cancer patient management, offering clinicians an additional tool to enhance precision in treatment selection and monitoring.
Research conducted by our long-term collaborators in Lyon and Taiwan consistently demonstrates that our Nu.Q® Cancer technology empowers clinicians to make more informed treatment decisions and provides valuable new monitoring capabilities throughout the patient journey.
By enriching clinical prognostication, Nu.Q® Cancer helps identify the most appropriate treatment pathway for an individual patient, supporting efforts to improve overall survival and deliver patient-centred care.
We are now on the path to the first use of Nu.Q® in clinical practice, an exciting prospect which is core to Volition's mission, using our tests to help save lives."
Read the full article here. -----
#5. VNRX Potential Catalyst - The First Sale Of Nu.Q® Cancer Assays Acts As A Major Milestone.
VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use
HENDERSON, Nev., Nov. 25, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the first sale of its Nu.Q® Cancer assays to one of Europe's leading cancer centers, the Hospices Civils de Lyon, in Lyon, France.
...
Dr. Andrew Retter, Chief Medical Officer, Volition, added:
"Research conducted by the team at Lyon demonstrates that Nu.Q® Cancer technology empowers clinicians to make more informed treatment decisions and provides valuable new monitoring capabilities throughout the patient journey. By enriching clinical prognostication, Nu.Q® Cancer helps identify the most appropriate treatment pathway for an individual patient, supporting efforts to improve overall survival and deliver patient-centred care.
Nu.Q® Cancer represents a significant advancement in lung cancer patient management, offering clinicians an additional tool to enhance precision in treatment selection and monitoring."
Mr. Gael Forterre, Chief Commercial Officer, Volition concluded:
"This is a major milestone for Volition in the commercialization and licensing of Nu.Q® in the human cancer field. We are now on the path to the first use of Nu.Q® in clinical practice, an exciting prospect which is core to Volition's mission, using our tests to help save lives. We look forward to providing more details soon."
...
Read the full article here. -----
(NYSE American: VNRX) Recap - 5 Potential Catalysts On Watch
#1. A Significant Analyst Target ($2.50) May Signal Triple-Digit Potential Upside.
#2. A Major Breakthrough Announced In Nu.Q® Vet Cancer Test Clinical Data.
#3. The Company Just Solved A "Needle In A Haystack" Problem With 180-Fold (18,000%) Enrichment.
#4. Volition Presents Two Abstracts At The NACLC (Now On the Path To The First Use Of Nu.Q® In Clinical Practice.
#5. The First Sale Of Nu.Q® Cancer Assays Acts As A Major Milestone. -----
Coverage is now officially underway on VolitionRx Limited (NYSE American: VNRX).
Be on the lookout for updates coming your way shortly. Talk soon.
Sincerely, Kai Parker StockWireNews
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 01/19/2026 and ending on 01/20/2026 to publicly disseminate information about (VNRX:US) via digital communications. Under this agreement, SWN Media LLC has been paid twenty thousand USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (VNRX:US).
Please see important disclosure information here: https://stockwirenews.com/disclosure/vnrx-g6zpb/#details | 
0 التعليقات:
إرسال تعليق